Last reviewed · How we verify
NCT04671862
Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis
NA trial testing Photobiomodulation in Mucositis Oral in 25 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | Ottawa Hospital Research Institute |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 25 |
| Start date | 1 June 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Photobiomodulation
Conditions studied
- Mucositis Oral — all drugs for Mucositis Oral →
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Radiation Dermatitis — all drugs for Radiation Dermatitis →
Sponsor
Ottawa Hospital Research Institute
Who can join
18 and older, any sex, with Mucositis Oral or Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try to reduce the occurence and severity of mucositis in patients treated with radiotherapy for head and neck cancer Previous studies in head and neck cancer patients have shown that photobiomodulation (light therapy) can prevent mucositis. There are currently no centers in Canada using this technique in routine practice, but this is recommended in International guidelines and widely used in Europe. The investigators therefore wish to implement this technique in Ottawa under the umbrella of a clinical trial to insure its safety and efficacy in a Canadian context.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ionizing radiation: molecular mechanisms, biological effects, and therapeutic targets.
Wei W, Ren Y, Lan J, Yi J, et al · · 2026 · PMID 41507636 · DOI 10.1186/s43556-025-00358-4
Verify or expand the search:
- PubMed search for NCT04671862
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Photobiomodulation
Trials testing the same drug.
- NCT07296068 — Can Acute Photobiomodulation Improve Balance and Cognition in Individuals With Ataxia: a Pilot Feasibility Placebo Rando · NA · not yet recruiting
- NCT07183267 — Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Year · NA · not yet recruiting
- NCT07476209 — Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia · NA · recruiting
- NCT06984796 — Photobiomodulation on Pain Perception During the Insertion of the T 380 Copper Intrauterine Device (IUD) · NA · not yet recruiting
- NCT07425080 — HELIOS Advanced: Human Oocyte Illumination to Enhance Development · NA · recruiting
Other Ottawa Hospital Research Institute trials
Trials by the same sponsor.
- NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
- NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
- NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
- NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
- NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04671862 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
- Last refreshed: 21 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04671862.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing